title: Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.
abstract: Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets. Thus, a set of NDGA analogs (7a-7h) was prepared and examined for inhibitory potency against IGF-1R kinase and an alternative target, 15-lipoxygenase (15 LOX). The anti-cancer effects of these compounds were determined by their ability to inhibit IGF-1 mediated cell growth of MCF-7 breast cancer cells. The design of the analogs was based upon a cursory Topliss approach in which one of NDGA's aromatic rings was modified with various substituents. Structural modification of one of the two catechol rings of NDGA was found to have little effect upon the inhibitory potency against both kinase activity of the IGF-1R and IGF-1 mediated cell growth of MCF-7 cells. 15-LOX was found to be most sensitive to structural modifications of NDGA. From the limited series of NDGA analogs examined, the compound that exhibited the greatest selectivity for IGF-1 mediated growth compared to 15-LOX inhibition was a cyclic analog 7h with a framework similar to a natural product isolated from Larrea divaricata. The results for 7h are significant because while NDGA displays biological promiscuity, 7h exhibits greater specificity toward the breast cancer target IGF-1R with that added benefit of possessing a 10-fold weaker potency against 15-LOX, an enzyme which has a purported tumor suppressing role in breast cancer. With increased specificity and potency, 7h may serve as a new lead in developing novel therapeutic agents for breast cancer.
authors.affiliation: Department of Chemistry & Biochemistry, San Francisco State University, San Francisco, CA 94132-4163, USA.
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Blecha
authors.forename: Marc O
authors.initials: MO
authors.lastname: Anderson
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Chow
authors.forename: Christle C
authors.initials: CC
authors.lastname: Guevarra
authors.forename: Celia
authors.initials: C
authors.lastname: Pender
authors.forename: Cristina
authors.initials: C
authors.lastname: Penaranda
authors.forename: Marianna
authors.initials: M
authors.lastname: Zavodovskaya
authors.forename: Jack F
authors.initials: JF
authors.lastname: Youngren
authors.forename: Clifford E
authors.initials: CE
authors.lastname: Berkman
mesh_terms: D001943:Breast Neoplasms / Q000473:pathology; D045744:Cell Line, Tumor; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D009637:Masoprocol / Q000031:analogs & derivatives / Q000494:pharmacology*; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors*
chemical_list: D016859:Lipoxygenase Inhibitors; D009637:Masoprocol; D017526:Receptor, IGF Type 1